Literature DB >> 25512630

Intrahepatic and Peripheral CXCL10 Expression in Hepatitis C Virus-Infected Patients Treated With Telaprevir, Pegylated Interferon, and Ribavirin.

Marija Zeremski1, Rositsa B Dimova2, Samantha Benjamin1, Marina S Penney3, Martyn C Botfield3, Andrew H Talal4.   

Abstract

UNLABELLED: We assessed peripheral and liver CXCL10 levels in 15 patients treated with telaprevir/pegylated interferon/ribavirin. Induction of peripheral CXCL10 messenger RNA (mRNA) peaked (mean fold-induction [±SD], 3.1 ± 1.9) between treatment hour 6 and day 2, while induction of intrahepatic CXCL10 mRNA peaked (mean fold-induction [±SD], 1.3 ± 0.54) at hour 10 or day 4. Peripheral CXCL10 levels were higher at treatment hour 10 (P = .032) and day 2 (P = .009) in patients with undetectable virus 2 weeks after treatment initiation. Treatment hour 10 (P = .023) and peak (P = .034) intrahepatic CXCL10 levels were also higher in these patients. CXCL10 did not distinguish treatment responders from nonresponders. In conclusion, CXCL10 identified very rapid virological response in patients treated with a direct-acting antiviral. CLINICAL TRIALS REGISTRATION: NCT00892697.
© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  CXCL10; HCV; chemokines; liver inflammation

Mesh：

Substances：

Year:  2014        PMID： 25512630      PMCID： PMC4506314          DOI： 10.1093/infdis/jiu807

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  15 in total

1.  Activation of chemokine and inflammatory cytokine response in hepatitis C virus-infected hepatocytes depends on Toll-like receptor 3 sensing of hepatitis C virus double-stranded RNA intermediates.

Authors:  Kui Li; Nan L Li; Dahai Wei; Susan R Pfeffer; Meiyun Fan; Lawrence M Pfeffer
Journal:  Hepatology       Date:  2012-01-30       Impact factor: 17.425

2.  Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C.

Authors:  David Butera; Svetlana Marukian; Amy E Iwamaye; Edgardo Hembrador; Thomas J Chambers; Adrian M Di Bisceglie; Edgar D Charles; Andrew H Talal; Ira M Jacobson; Charles M Rice; Lynn B Dustin
Journal:  Blood       Date:  2005-04-28       Impact factor: 22.113

3.  Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection.

Authors:  Ana I Romero; Martin Lagging; Johan Westin; Amar P Dhillon; Lynn B Dustin; Jean-Michel Pawlotsky; Avidan U Neumann; Carlo Ferrari; Gabriele Missale; Bart L Haagmans; Solko W Schalm; Stefan Zeuzem; Francesco Negro; Elke Verheij-Hart; Kristoffer Hellstrand
Journal:  J Infect Dis       Date:  2006-08-29       Impact factor: 5.226

4.  Direct, interferon-independent activation of the CXCL10 promoter by NF-κB and interferon regulatory factor 3 during hepatitis C virus infection.

Authors:  Jessica Brownell; Jacob Bruckner; Jessica Wagoner; Emmanuel Thomas; Yueh-Ming Loo; Michael Gale; T Jake Liang; Stephen J Polyak
Journal:  J Virol       Date:  2013-11-20       Impact factor: 5.103

5.  CXCL9 and CXCL10 chemokines as predictors of liver fibrosis in a cohort of primarily African-American injection drug users with chronic hepatitis C.

Authors:  Marija Zeremski; Rositsa Dimova; Jacquie Astemborski; David L Thomas; Andrew H Talal
Journal:  J Infect Dis       Date:  2011-09-15       Impact factor: 5.226

6.  Telaprevir-based treatment effects on hepatitis C virus in liver and blood.

Authors:  Andrew H Talal; Rositsa B Dimova; Eileen Z Zhang; Min Jiang; Marina S Penney; James C Sullivan; Martyn C Botfield; Ananthsrinivas Chakilam; Rishikesh Sawant; Christine M Cervini; Marija Zeremski; Ira M Jacobson; Ann D Kwong
Journal:  Hepatology       Date:  2014-07-31       Impact factor: 17.425

Review 7.  The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection.

Authors:  M Zeremski; L M Petrovic; A H Talal
Journal:  J Viral Hepat       Date:  2007-10       Impact factor: 3.728

8.  Independent, parallel pathways to CXCL10 induction in HCV-infected hepatocytes.

Authors:  Jessica Brownell; Jessica Wagoner; Erica S Lovelace; Derek Thirstrup; Isaac Mohar; Wesley Smith; Silvia Giugliano; Kui Li; I Nicholas Crispe; Hugo R Rosen; Stephen J Polyak
Journal:  J Hepatol       Date:  2013-06-12       Impact factor: 25.083

9.  Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection.

Authors:  Marija Zeremski; Rositsa Dimova; Queenie Brown; Ira M Jacobson; Marianthi Markatou; Andrew H Talal
Journal:  J Infect Dis       Date:  2009-12-01       Impact factor: 5.226

10.  Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C.

Authors:  Marija Zeremski; Lydia M Petrovic; Luis Chiriboga; Queenie B Brown; Herman T Yee; Milan Kinkhabwala; Ira M Jacobson; Rositsa Dimova; Marianthi Markatou; Andrew H Talal
Journal:  Hepatology       Date:  2008-11       Impact factor: 17.425
View more
  5 in total

1.  Intrahepatic Sampling for the Elucidation of Antiviral Clinical Pharmacology.

Authors:  Charles S Venuto; Andrew H Talal
Journal:  Clin Pharmacol Drug Dev       Date:  2017-03

2.  Interferon Alpha Subtype-Specific Suppression of HIV-1 Infection In Vivo.

Authors:  Kerry J Lavender; Kathrin Gibbert; Karin E Peterson; Erik Van Dis; Sandra Francois; Tyson Woods; Ronald J Messer; Ali Gawanbacht; Janis A Müller; Jan Münch; Katie Phillips; Brent Race; Michael S Harper; Kejun Guo; Eric J Lee; Mirko Trilling; Hartmut Hengel; Jacob Piehler; Jens Verheyen; Cara C Wilson; Mario L Santiago; Kim J Hasenkrug; Ulf Dittmer
Journal:  J Virol       Date:  2016-06-10       Impact factor: 5.103

3.  Regulatory polymorphism of CXCL10 rs1439490 in seronegative occult hepatitis C virus infection.

Authors:  Xu Wang; Song Wang; Zhen-Hua Liu; Wen-Qian Qi; Qian Zhang; Yong-Gui Zhang; De-Rong Sun; Yan Xu; Hong-Guang Wang; Zhong-Xie Li; Xian-Ling Cong; Ping Zhao; Chang-Yu Zhou; Jiang-Bin Wang
Journal:  World J Gastroenterol       Date:  2018-05-28       Impact factor: 5.742

Review 4.  Immunomodulation of CXCL10 Secretion by Hepatitis C Virus: Could CXCL10 Be a Prognostic Marker of Chronic Hepatitis C?

Authors:  Silvia Martina Ferrari; Poupak Fallahi; Ilaria Ruffilli; Giusy Elia; Francesca Ragusa; Sabrina Rosaria Paparo; Armando Patrizio; Valeria Mazzi; Michele Colaci; Dilia Giuggioli; Clodoveo Ferri; Alessandro Antonelli
Journal:  J Immunol Res       Date:  2019-08-08       Impact factor: 4.818

5.  Intrahepatic Viral Kinetics During Direct-Acting Antivirals for Hepatitis C in Human Immunodeficiency Virus Coinfection: The AIDS Clinical Trials Group A5335S Substudy.

Authors:  Ashwin Balagopal; Laura M Smeaton; Jeffrey Quinn; Charles S Venuto; Gene D Morse; Vincent Vu; Beverly Alston-Smith; Daniel E Cohen; Jorge L Santana-Bagur; Donald D Anthony; Mark S Sulkowski; David L Wyles; Andrew H Talal
Journal:  J Infect Dis       Date:  2020-07-23       Impact factor: 7.759
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.